Bicara CFO trades 16,518 shares under 10b5-1

Bicara Therapeutics Chief Financial Officer Hyep Ivan reported option exercises and share sales in early March 2026.

Rhea-AI Filing Summary

Bicara Therapeutics Chief Financial Officer Hyep Ivan reported option exercises and share sales in early March 2026. On March 3–4, he exercised stock options to acquire a total of 16,518 shares of common stock at a reported exercise price of $3.7898 per share. He then sold 16,518 common shares in two open-market transactions at weighted-average prices of $18.2154 and $18.2456 per share, under a Rule 10b5-1 trading plan adopted on February 13, 2025.

After these transactions, he directly owned 145,355 shares of Bicara common stock and held stock options covering 79,784 shares, subject to vesting in equal quarterly installments following April 5, 2023 and August 8, 2023, contingent on his continued service.

Insider Trade Summary

Exercise and Sale: 16,518 shares ($238K approx. pre-tax spread)

Exercise and Sale 8 txns

Insider Hyep Ivan

Role Chief Financial Officer

Sold 16,518 shs ($301K)

Approx. gross sale proceeds $301K

Approx. exercise cost $63K

Approx. pre-tax spread $238K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,963	$0.00	$0.00
Exercise	Common Stock	2,963	$3.7898	$11K
Sale	Common Stock	2,963	$18.2456	$54K
Exercise	Stock Option (Right to Buy)	7,318	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	6,237	$0.00	$0.00
Exercise	Common Stock	7,318	$3.7898	$28K
Exercise	Common Stock	6,237	$3.7898	$24K
Sale	Common Stock	13,555	$18.2154	$247K

Holdings After Transaction: Stock Option (Right to Buy) — 137,928 contracts (Direct); Common Stock — 145,355 shares (Direct)

Footnotes (5)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
4. F4. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
5. F5. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bicara Therapeutics (BCAX) CFO Hyep Ivan report in this Form 4?

He reported exercising stock options and selling shares. Across March 3–4, 2026, he exercised options for 16,518 Bicara common shares at $3.7898 and sold 16,518 shares in open-market trades at weighted-average prices above $18 under a Rule 10b5-1 plan.

How many Bicara Therapeutics (BCAX) shares did the CFO sell?

He sold 16,518 common shares. The Form 4 shows two open-market sale transactions: 2,963 shares at a weighted-average price of $18.2456 and 13,555 shares at a weighted-average price of $18.2154, executed within specified intraday price ranges.

Were the Bicara Therapeutics (BCAX) CFO’s stock sales pre-planned?

Yes, they were made under a Rule 10b5-1 trading plan. A footnote states the transactions were executed pursuant to a Rule 10b5-1 plan adopted on February 13, 2025, indicating a pre-established schedule for trades rather than discretionary same-day decisions.

What is the Bicara Therapeutics (BCAX) CFO’s ownership after these transactions?

He directly holds 145,355 common shares afterward. The filing also reports stock options for 79,784 shares remaining outstanding, which vest in sixteen equal quarterly installments starting after April 5, 2023 and August 8, 2023, subject to continued service conditions.

At what prices did the Bicara Therapeutics (BCAX) CFO sell his shares?

The sales occurred around the mid‑$18 range. One sale used a weighted-average price of $18.2154 with trades from $18.15 to $18.31; the other used $18.2456, with trades between $18.15 and $18.44, as detailed in the footnotes.

What are the vesting terms of the Bicara Therapeutics (BCAX) CFO’s stock options?

The options vest in equal quarterly installments. Shares underlying the reported options vest in sixteen equal quarterly installments following April 5, 2023 and August 8, 2023, and each vesting date requires the CFO’s continued service with Bicara Therapeutics to receive the corresponding portion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 07:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hyep Ivan

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M(1)		7,318	A	$3.7898	152,673	D
Common Stock	03/03/2026		M(1)		6,237	A	$3.7898	158,910	D
Common Stock	03/03/2026		S(1)		13,555	D	$18.2154(2)	145,355	D
Common Stock	03/04/2026		M(1)		2,963	A	$3.7898	148,318	D
Common Stock	03/04/2026		S(1)		2,963	D	$18.2456(3)	145,355	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.7898	03/03/2026		M(1)			7,318	(4)	04/05/2033	Common Stock	7,318	$0	58,144	D
Stock Option (Right to Buy)	$3.7898	03/03/2026		M(1)			6,237	(5)	08/08/2033	Common Stock	6,237	$0	82,747	D
Stock Option (Right to Buy)	$3.7898	03/04/2026		M(1)			2,963	(5)	08/08/2033	Common Stock	2,963	$0	79,784	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

4. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.

5. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Lara Meisner, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.